We then investigated whether TNIKi treatments trigger its potent CD8+ T cell-mediated antitumor responses solely by inducing immunogenic tumor cell death[9] or alternatively by directly activating CD8+ T cell. The gene discussed is CD8A; the disease is neoplasm.